Table 2.
Experimental therapies prescribed to patients with postprandial distress syndrome (group A) and patients with epigastric pain syndrome (group B) during the study, assessed at T0 (start of the study period) and at T1 (15 days following the end of the 30-day treatment period).
|
Study group |
||||||||
|---|---|---|---|---|---|---|---|---|
|
A |
B |
|||||||
| T0 n = 1357 | T1 n = 628 | T0 n = 1319 | T1 n = 520 | |||||
| Experimental therapy | n | % | n | % | n | % | n | % |
| Probiotic | 498 | 36.7 | 270 | 43 | 269 | 20.4 | 131 | 25.2 |
| Probiotic plus proton-pump inhibitor | 390 | 28.7 | 131 | 20.9 | 725 | 55 | 268 | 51.5 |
| Probiotic plus prokinetics | 327 | 24.1 | 146 | 23.2 | 152 | 11.5 | 58 | 11.2 |
| Probiotic plus antacids | 142 | 10.5 | 81 | 12.9 | 173 | 13.1 | 63 | 12.1 |